Clinical trials: Severe Pneumonia
Severe Pneumonia Caused by Multidrug-resistant Gram-negative Bacterial Infection
A Study on Integrated Chinese and Western Medicine for Severe Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacterial Infections
This study aims to evaluate the clinical efficacy of a traditional Chinese medicine formula granule (Feireqing Granules) in the treatment of severe pneumonia caused by multidrug-resistant Gram-negative bacterial infections…
- Trial name
- NCT07206745
- Testing
- Fei Re Qing Granules
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Henan University of Traditional Chinese Medicine
COVID-19, SARS-CoV2 Infection
Awake Prone Positioning in Moderate to Severe COVID-19
The purpose of this study is comparing vital signs between standard care and prone position groups. Standard care will consist of routine clinical care, including any advice to lie in prone position as routinely recommended by…
- Conditions
- COVID-19, SARS-CoV2 Infection, COVID-19 Acute Respiratory Distress Syndrome, Acute Hypoxemic Respiratory Failure
- Trial name
- NCT05083130
- Testing
- a wake prone positioning
- Where
- Vietnam
- Volunteers
- 93 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Mechanically Ventilated Patients, Severe Pneumonia
Impact of a High-Protein Diet on Clinical Outcomes in Mechanically Ventilated Patients With Severe Pneumonia
prospective, comparative, observational study will be conducted at the Critical Care Department, Fayoum University Hospital, to evaluate the impact of a high-protein diet versus a standard-protein diet in mechanically ventilated…
- Trial name
- NCT07634328
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Fayoum University
Psoriasis
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01163253
- Testing
- CP-690,550
- Where
- 323 sites in United States, Argentina and 34 more
- Volunteers
- 2,867 people
- Sponsor
- Pfizer
Pneumonia, Pneumococcal
Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia
The purpose of this study is to compare levofloxacin vs ceftriaxone impact on the cytokine production in patients with pneumococcal pneumonia.
- Trial name
- NCT00429975
- Testing
- levofloxacin, ceftriaxone
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- Hospital Mutua de Terrassa
Pneumonia, Viral, Covid19
Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19
Introduction: SARS-CoV2 infection produces severe pneumonia with pulmonary alveolar collapse. There is no specific treatment to date.
- Conditions
- Pneumonia, Viral, Covid19, ARDS, Oxidative Stress
- Trial name
- ANTIOX-COVID (NCT04570254)
- Testing
- Vitamin C, Vitamin E, Melatonin
- Where
- Mexico
- Volunteers
- 110 people
- Sponsor
- Unidad Temporal COVID-19 en Centro Citibanamex
SARS-CoV Infection, COVID-19
CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19
There is emerging evidence that patients with SARS-CoV-2 are affected by increased coagulopathy, including in the most advanced forms, a fully blown disseminated intravascular coagulation, leading to multi organ failure (MOF).
- Trial name
- CONVINCE (NCT04516941)
- Testing
- Edoxaban Tablets, Colchicine Tablets
- Where
- 5 sites in Belgium, Italy and 1 more
- Volunteers
- 60 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
COVID-19
EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19
The purpose of this study is to determine whether PF-07321332/ritonavir is safe and effective for the treatment of adults who are ill with COVID-19 and do not need to be in the hospital, but are at an increased risk of developing…
- Trial name
- NCT04960202
- Testing
- PF-07321332, Ritonavir
- Where
- 201 sites in United States, Argentina and 18 more
- Volunteers
- 2,091 people
- Sponsor
- Pfizer
Covid19
The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection
This is an adaptive, Phase I/II study in 2 parts: Part 1 is to evaluate the Maximum Tolerable Dose (MTD) , tolerance, safety and pharmacokinetics of FB2001 in healthy subjects; Part 2 is to evaluate the safety, pharmacokinetics…
- Trial name
- NCT04766931
- Testing
- FB2001
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Frontier Biotechnologies Inc.
COVID-19 Pandemic
Investigation on the Epidemic Prevention Effect of Using Chinese Medicine During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak.
Taking a regional hospital as an example, the investigators will discuss the changes in the community cumulative incidence rate(CIR) and the epidemic prevention effect of using Chinese medicine during the SARS-CoV-2 outbreak.
- Trial name
- NCT05236309
- Testing
- Jing-Guan-Fang(JGF) : Chinese herbal decoction
- Where
- Taiwan
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Taipei City Hospital
Severe COVID-19
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
The purpose of this Phase 2 study is to test safety, efficacy, and tolerability of an oral preparation of VB-201 in patients with severe COVID-19
- Trial name
- NCT04733833
- Testing
- VB-201 + Standard of care, Standard of care
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
Hemoglobinopathies, Sickle Cell Disease
ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19
Patients with red blood cell disorders (RBCDs), such as Sickle cell disease (SCD) and Thalassemia, are chronic, life-threatening conditions that can become multi-organ complications over time, and are likely at an increased risk…
- Conditions
- Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Anemia, Sickle Beta Thalassemia
- Trial name
- NCT06831799
- Testing
- Non applicable, is a patient registry
- Where
- Spain
- Volunteers
- 684 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Covid19, SARS-CoV Infection
A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition
The co-primary objectives of this study are to: 1. Determine and compare the COVID-19 antibody positivity rate in health care workers and patients without a known COVID-19 infection 2.
- Trial name
- START (NCT04573634)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Jill M Kolesar
Intensive Care Unit Syndrome, Community-acquired Pneumonia
Pharmacokinetics of Levofloxacin in Intensive Care Unit
The aim of this study is 1. to describe levofloxacin pharmacokinetics in ICU patients suffering from pneumonia with taking into account physio-pathological parameters. 2.
- Trial name
- LEVO-PHARM (NCT02018081)
- Testing
- Levofloxacin
- Where
- France
- Volunteers
- 52 people
- Sponsor
- University Hospital, Toulouse
Infectious Disease of Lung, Molecular Diagnosis
Clinical Impact of a Multiplex Rapid Diagnostic Pneumonia Panel Testing in Critically-ill Patients With Severe Hospital-acquired Pneumonia, Ventilator-associated Pneumonia and Community-acquired Pneumonia With High Risk of Multidrug Resistant Pathogen
The objective of the research is to ascertain the influence of a syndromic mutiplex PCR assay (FilmArray) on the management of patients hospitalised in the ICU for severe respiratory disease.
- Conditions
- Infectious Disease of Lung, Molecular Diagnosis, Pneumonia
- Trial name
- NCT06782607
- Testing
- Pneumonia Panel by FilmArray
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Mahidol University
Severe Pneumonia, Immunosuppressed Hosts
Molecular Diagnosis and Prognosis of Severe Pulmonary Infection Immunosuppressed Hosts
Serious pneumonia is a serious inflammation of the lungs caused by various pathogens, resulting in severe bacteraemia or toxemia, which in turn causes blood pressure drop, shock, blurred consciousness, restlessness, delirium and…
- Conditions
- Severe Pneumonia, Immunosuppressed Hosts, Diagnosis
- Trial name
- NCT04395066
- Testing
- CD55
- Volunteers
- 171 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
COVID-19
Specimen Collection Study From Coronavirus Disease 2019 (COVID-19) Vaccinated Adults and Adolescents
This is a specimen collection study intended to generate a biological specimen repository of samples from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve adults and adolescents ≥12 years old who will receive…
- Trial name
- CoVacSpec (NCT05252910)
- Where
- 32 sites in United States, Colombia and 5 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Pharm-Olam, LLC
Severe Pneumonia
Reparixin in COVID-19 Pneumonia - Efficacy and Safety
Phase 2 Study Objectives: efficacy and safety of of Reparixin treatment as compared to the control arm in adult patients with severe COVID-19 pneumonia Phase 3 Study Objectives: efficacy and safety of Reparixin treatment as…
- Trial name
- NCT04794803
- Testing
- Reparixin, Standard of care
- Where
- 4 sites in Brazil, Italy
- Volunteers
- 56 people
- Sponsor
- Dompé Farmaceutici S.p.A
Community Acquired Pneumonia, Respiration Failure
A Molecular Toolkit for the Microbial Investigation of Severe Community Acquired Pneumonia
Severe community acquired pneumonia is common and associated with high mortality. Conventional microbiological diagnostics identify pathogens in approximately half of cases, which is inadequate for both clinical and…
- Conditions
- Community Acquired Pneumonia, Respiration Failure, Pneumonia
- Trial name
- S-CAP (NCT02963142)
- Where
- United Kingdom
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Pneumonia
P4 Peptide in Community Acquired Pneumonia
The investigators' aim is to find out whether immune cells from patients with a severe chest infection will react ex vivo to a new immunomodulating peptide, P4 as part of augmented passive immunotherapy The investigators know…
- Trial name
- P4 (NCT03497962)
- Testing
- Venepuncture, Bronchoscopy
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.